A Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ShK-186

Trial Profile

A Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ShK-186

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2015

At a glance

  • Drugs Dalazatide (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions
  • Sponsors Kineta
  • Most Recent Events

    • 27 Nov 2013 New trial record
    • 26 Nov 2013 The first subject has been enrolled, according to a Kineta media release. Results are expected in mid-2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top